Drug intelligence / Profile preview

DAA1106

Development stage: Preclinical
Modality: Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

DAA1106 is a potent and selective agonist for the peripheral benzodiazepine receptor (PBR), also known as the translocator protein (TSPO). It is used in its radiolabeled form, such as [11C]DAA1106, for positron emission tomography (PET) imaging to examine neuroinflammation. DAA1106 exhibits anxiolytic-like effects in animal studies but does not interact with the GABA_A receptor.

Other names: N-(2,5-Dimethoxybenzyl)-N-(5-fluoro-2-phenoxyphenyl)acetamide

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on DAA1106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DAA1106.

Explore the full profile